RE:Why I think SVA is a good speculationDepends on the terms of the deal. If it isn't spectacular it'll fall hard. I know I'll be selling my position if I'm not happy and likely others will as well. If it is a good deal then the partner and terms will determine where we go. I personally think it'll be an OK deal and we get to see 3 dollars max is the markets don't continue to buckle but more likely 2 to 2.50 if we are lucky. Maybe less if we continue to drop to 1.20 again.
Stockfshr wrote: Pouch: No fibrosis; donor cells work for two T1D patients so far
Cell strategy: Currently - donor cells; Better - Potential use of stem cells
Immune suppression strategy: Currently - drugs; Better? - Potential use of conformal coating through collaboration with University of Miami; Best? - Potential blue sky using AgeX UniverCyte gene editing
Confidential collaboration agreements with multiple pharmaceutical industry leaders
Potential competitors are stumbling making SVA more attractive: SANA, Sigilon
Huge diabetes T1D market. Additional potential markets: Hemophilia A; Thyroid disease. Tip of the iceberg?
Multiple shots on goal; steady progress.
Great management with proven individual success histories
Stock price recently shot up to $2.24 on hopes of a partnership deal on the anniversary of the last big news of collaborations. Imagine what could happen with actual news....
Thoughts?